JP2011136997A5 - - Google Patents

Download PDF

Info

Publication number
JP2011136997A5
JP2011136997A5 JP2011000275A JP2011000275A JP2011136997A5 JP 2011136997 A5 JP2011136997 A5 JP 2011136997A5 JP 2011000275 A JP2011000275 A JP 2011000275A JP 2011000275 A JP2011000275 A JP 2011000275A JP 2011136997 A5 JP2011136997 A5 JP 2011136997A5
Authority
JP
Japan
Prior art keywords
nucleic acid
protein
nucleotide sequence
mammal
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011000275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011136997A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011136997A publication Critical patent/JP2011136997A/ja
Publication of JP2011136997A5 publication Critical patent/JP2011136997A5/ja
Withdrawn legal-status Critical Current

Links

JP2011000275A 2003-09-17 2011-01-04 コンセンサス／先祖免疫原 Withdrawn JP2011136997A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50346003P 2003-09-17 2003-09-17
US60/503,460 2003-09-17
US60472204P 2004-08-27 2004-08-27
US60/604,722 2004-08-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006527030A Division JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013253689A Division JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Publications (2)

Publication Number Publication Date
JP2011136997A JP2011136997A (ja) 2011-07-14
JP2011136997A5 true JP2011136997A5 (enExample) 2011-08-25

Family

ID=34381074

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006527030A Expired - Fee Related JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原
JP2011000275A Withdrawn JP2011136997A (ja) 2003-09-17 2011-01-04 コンセンサス／先祖免疫原
JP2013253689A Expired - Fee Related JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006527030A Expired - Fee Related JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013253689A Expired - Fee Related JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Country Status (10)

Country Link
US (3) US8071107B2 (enExample)
EP (2) EP1667714B1 (enExample)
JP (3) JP4773352B2 (enExample)
KR (2) KR20070028291A (enExample)
CN (2) CN1852734B (enExample)
AU (1) AU2004274937B9 (enExample)
BR (1) BRPI0414443A (enExample)
CA (2) CA2539325C (enExample)
IL (3) IL174380A0 (enExample)
WO (1) WO2005028625A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150961A0 (en) 2000-02-04 2003-02-12 Univ Duke Human immunodeficiency virus vaccine
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
US7101552B2 (en) 2000-09-22 2006-09-05 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
US8048431B2 (en) * 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
WO2007018550A2 (en) 2004-09-08 2007-02-15 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Compositions and methods for the detection of hiv-1/hiv-2 infection
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
UA97800C2 (uk) * 2006-03-10 2012-03-26 Пептселл Лімітед Пептидні послідовності і композиції
WO2007126959A2 (en) * 2006-03-29 2007-11-08 Dana-Farber Cancer Institute Methods and compositions for inducing an immune response to hiv and models for testing
EP2399602B1 (en) * 2006-06-02 2014-11-26 International AIDS Vaccine Initiative HIV-1 Clade A consensus sequences, antigens, and transgenes
KR101999376B1 (ko) 2006-07-28 2019-07-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
EP2129395A4 (en) * 2007-03-27 2012-05-09 Univ California ACUTE, TRANSFERRED HIV ENVELOPMENT SIGNATURES
NZ593598A (en) 2008-11-18 2013-02-22 Beth Israel Hospital Optimized antiviral vaccines with improved cellular immunogenicity
WO2011106100A2 (en) 2010-02-25 2011-09-01 Duke University Method of inducing the production of protective anti-hiv-1 antibodies
US20130177583A1 (en) * 2010-03-03 2013-07-11 Duke University Molecular clone of hiv-1
WO2012047267A2 (en) * 2010-09-28 2012-04-12 Duke University Polyvalent immunogen
EP2492279A1 (en) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2739300B1 (en) 2011-07-05 2019-06-19 Duke University N-terminal deleted gp120 immunogens
US10092638B2 (en) 2011-10-03 2018-10-09 Duke University GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9415099B2 (en) 2012-03-02 2016-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of altering the immundominance hierarchy of HIV gag by DNA vaccine expressing conserved regions
EP2877207A1 (en) * 2012-07-24 2015-06-03 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR101826536B1 (ko) 2012-08-07 2018-02-07 현대자동차 주식회사 차량의 아이들 스톱 제어 방법 및 장치
WO2014151687A2 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods to treat aids
EP3058065B1 (en) * 2013-10-16 2018-05-02 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2017007646A1 (en) * 2015-07-07 2017-01-12 International Aids Vaccine Initiative Hiv-1 clade c envelope glycoproteins
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
WO2017152146A2 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
LT3512543T (lt) * 2016-09-15 2020-11-10 Janssen Vaccines & Prevention B.V. Trimerą stabilizuojančios živ apvalkalo baltymo mutacijos
US10828363B1 (en) * 2016-09-16 2020-11-10 The Trustees Of The University Of Pennsylvania Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
EP3526236B1 (en) 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CA3114870A1 (en) 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
CN116322757A (zh) 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
US20250213675A1 (en) * 2022-03-31 2025-07-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv
WO2025072797A2 (en) * 2023-09-27 2025-04-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
AU2001245294B2 (en) 2000-02-18 2006-11-16 University Of Washington Aids ancestral viruses and vaccines
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US7101552B2 (en) 2000-09-22 2006-09-05 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
US8048431B2 (en) 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
HRP20040589B1 (en) 2004-06-28 2011-07-31 Biljan Marijan The stand for garment hangers with a built-in counter

Similar Documents

Publication Publication Date Title
JP2011136997A5 (enExample)
JP2011530309A5 (enExample)
JP2012126742A5 (enExample)
JP2013172734A5 (enExample)
JP2011155981A5 (enExample)
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
EP4509189A3 (en) Anti-fcrn antibodies
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
HUE054437T2 (hu) Anti-CGRP készítmények és alkalmazásuk
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
CO7151522A2 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
CL2013002361A1 (es) Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína;
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
EP4276180A3 (en) Clostridium histolyticum enzyme
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
EP2897640A4 (en) HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIBODY PROTEIN AND VACCINE THEREWITH
PT2672992T (pt) Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma
CL2012002016A1 (es) Vector para vacunas que comprende un polipeptido antigénico y un polipéptido hmgb1 o un fragmento funcional; composición que comprende el vector; método para potenciar respuesta inmune en un sujeto.
PL2776460T3 (pl) Białko fuzyjne zawierające interleukinę 4 i interleukinę 10
IN2012DN03209A (enExample)
BR112013018742A2 (pt) cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática
HUE050438T2 (hu) Rekombináns fehérjék és terápiás alkalmazásuk
WO2011094357A8 (en) Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
Casals et al. Next-generation sequencing approaches for genetic mapping of complex diseases
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH